Tumor Treatment Field Therapy (TTFT) Final LCD (L34823) and Response to Comments (RTC) Article Published
Joint DME MAC Publication
Today, the DME MACs published the Tumor Treatment Field Therapy (TTFT) Final LCD (L34823) and LCD-related Policy Article (PA) (A52711). The policy extends coverage of TTFT as a treatment option for Medicare beneficiaries with newly diagnosed glioblastoma multiforme (GBM). The posting of the final LCD marks the beginning of the 45-day notice period. The final LCD will be effective for claims with dates of service on or after September 1, 2019.
The DME MACs have also posted a response to all written comments received during the comment period, in a Response to Comments (RTC) Article (A56688).
Please refer to each DME MAC web site for additional information about policy development and copies of the final LCD.
Last Updated Jul 18, 2019